




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 309/32, C07C 59/48, 205/56	A1	(11) International Publication Number: WO 99/12919 (43) International Publication Date: 18 March 1999 (18.03.99)
(21) International Application Number: PCT/US98/17993 (22) International Filing Date: 3 September 1998 (03.09.98) (30) Priority Data: 60/058,618 11 September 1997 (11.09.97) US (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GAGE, James, R. [US/US]; 341 Point-O-Woods, Portage, MI 49002 (US). KELLY, Robert, C. [US/US]; 936 East Gull Lake Drive, Augusta, MI 49012 (US). HEWITT, Bradley, D. [US/US]; 6300 Woodlea, Kalamazoo, MI 49004 (US). (74) Agent: STEIN, Bruce; Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATES USEFUL AS PROTEASE INHIBITORS

(57) Abstract

Disclosed is a novel process and novel intermediates to prepare [R-(R*,R*)]-N-[3-[1-[5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide (XIX) which is a protease inhibitor useful in treating humans infected with the HIV virus.



(XIX)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATES USEFUL AS PROTEASE INHIBITORS

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention is a novel process and novel intermediates to prepare
5 [R-(R*,R*)]-N-[3-[1-[5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide (XIX) which is a protease inhibitor useful in treating humans infected with the HIV virus.

2. Description of the Related Art

[R-(R*,R*)]-N-[3-[1-[5,6-Dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-
10 2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide (XIX) can be produced by the process set forth in International Publications WO95/30670 and WO94/11361.

J. Med. Chem., 39(22), 4349 (1996) discloses the cyclic ester (VI) but in the racemic form. This document also discloses the transformation of the cyclic ester
15 (VI) to the protease inhibitor (XIX) but by a different synthetic pathway.

J. Am. Chem. Soc., 111, 3627 (1997) discloses the amino compound (XVIII).

Tetrahedron Letters, 34(2), 277-280 (1993) discloses a method for the conversion of a β -hydroxycarbonyl compound to a ring similar to that of formulas (VI) and (CVI). The β -hydroxycarbonyl compound in the prior art is a secondary
20 alcohol and that in the present invention is a tertiary alcohol. In addition, the processes are completely different with the process of *Tetrahedron Letters* not being operable on the tertiary alcohols (IV) and (CIV) of the present invention.

J. Med. Chem., 39(23), 4630-4642 (1996) discloses a method to make compounds similar to that of formulas (VI) and (CVI) but in racemic form from
25 starting materials different from the present invention by an unrelated method.

International Publication WO95/14012 claims a cyclic compound similar to the cyclic compounds (VI), (XVII) and (XXV) of the present invention but in racemic form. The process of the present invention produces these compounds in optically pure form.

30 **SUMMARY OF INVENTION**

Disclosed is (R)-3-hydroxy-3-(2-phenylethyl)hexanoic acid (IV) and pharmaceutically acceptable salts thereof.


Also disclosed is (6R)-5,6-dihydro-4-hydroxy-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one.

35 Further disclosed is [3 α (R),6(R)]5,6-dihydro-4-hydroxy-3-[1-(3-nitrophenyl)propyl]-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (XVII).

Additionally disclosed is (S)-methyl 3-(3-nitrophenyl)pentanoate.

Also disclosed is [3 α (R),6(R)]5,6-dihydro-4-hydroxy-3-[(Z)-1-(3-nitrophenyl)propenyl]-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one.

Also disclosed is a process for the production of the hydroxy lactone of
5 formula (CVI)



where R₁ is:

- 15 C₁-C₆ alkyl,
cyclohexyl,
phenyl,
-CH₂-CH₂- ϕ R₁₋₁ where R₁₋₁ is
-OH (and protected forms thereof),
20 -NH₂ (and protected forms thereof),
-H,
-NH-CO-CH₃,
-N(-CO-CH₃)₂;


where R₂ is:

- 25 C₁-C₆ alkyl,
cyclohexyl,
phenyl,
-CH₂-CH₂- ϕ R₂₋₁ where R₂₋₁ is
-OH (and protected forms thereof),
30 -NH₂ (and protected forms thereof),
-H,
-NH-CO-CH₃,
-N(-CO-CH₃)₂;

which comprises:

- 35 (1) contacting a salt of the formula (CIV)

5




(CIV)

with an acid to produce a free acid,

- (2) extracting the free acid from the reaction mixture,
- 10 (3) contacting the free acid with an activating agent,
- (4) contacting the reaction mixture of free acid/activating agent with malonate monoester and a divalent metal,
- (5) contacting the reaction mixture of step (4) with an acid,
- (6) contacting the reaction mixture of step (5) with a base in the presence of a
- 15 C₁-C₄ alcohol, THF or DMF.

Further disclosed is a process for the production of the hydroxy lactone of formula (CVI)

20



(CVI)

25 where R₁ is:

C₁-C₆ alkyl,

cyclohexyl,

phenyl,

-CH₂-CH₂-φR₁₋₁ where R₁₋₁ is

- 30 -OH (and protected forms thereof),
- NH₂ (and protected forms thereof),
- H,
- NH-CO-CH₃,
- N(-CO-CH₃)₂;

35 where R₂ is:

C₁-C₆ alkyl,

cyclohexyl,

phenyl,

-CH₂-CH₂-φR₂₋₁ where R₂₋₁ is

-OH (and protected forms thereof),

5 -NH₂ (and protected forms thereof),


-H,

-NH-CO-CH₃,

-N(-CO-CH₃)₂;

which comprises:

10 (1) contacting the anion of the formula (CIV)



15

or the free acid form thereof with an activating agent,

(2) contacting the reaction mixture of free acid/activating agent with
20 malonate monoester and a divalent metal,

(3) contacting the reaction mixture of step (4) with an acid,

(4) contacting the reaction mixture of step (5) with a base in the presence of a
C₁-C₄ alcohol, THF or DMF.

DETAILED DESCRIPTION OF THE INVENTION

25 The present invention is a novel process with novel intermediates to prepare [R-(R*,R*)]-N-[3-[1-[5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide (XIX) which is known to be a protease inhibitor and useful in treating humans infected with HIV.

CHART A discloses the transformation of the ketone (I) to the
30 corresponding keto-ester (II), to the corresponding acid (III), to the corresponding salt (IV), to the corresponding keto-alcohol (V) and finally to the corresponding cyclic ester (VI); see also EXAMPLEs 1 thru 4 and the preferred method, EXAMPLE 18.

CHART B discloses the transformation of 4-chlorothiophenol (VII) to the
corresponding chloroether (VIII), to the corresponding biphenyl compound (IX); see
35 also EXAMPLEs 5 and 6.

CHART C discloses the condensation of the biphenyl compound (IX) with the

salt (IV) to give the ester ether (X), and the transformations of the ester ether (X) to the corresponding alcohol (XI) and to the corresponding aldehyde (XII). Also disclosed is the coupling of the optically pure nitroester (XIII) with the aldehyde (XII) to produce the corresponding nitroether (XIV); see also EXAMPLEs 7 thru 10.

5 CHART D discloses the transformations of the nitroether (XIV) to the corresponding nitroketone (XV), to the corresponding nitroalcohol (XVI), to the corresponding nitro- α,β -unsaturated ester (XVII), to the corresponding amino compound (XVIII) and to the corresponding protease inhibitor (XIX); see also EXAMPLEs 11 thru 15.

10 CHART E discloses the preparation of the optically pure nitroester (XIII) which is used in CHART C. CHART E discloses the optical resolution of the racemic 1-(3-nitrophenyl)propanol (XX) to produce the corresponding optically pure 1-(3-nitrophenyl)propanol (XXI) and its transformation to the corresponding methylsulfonate (XXII), to the corresponding diester (XXIII), to the corresponding
15 nitroacid (XXIV) and to the corresponding optically pure nitroester (XIII); see also PREPARATIONS 1-5.

CHART F discloses an alternate, and preferable, route for the transformation of the cyclic ester (VI) to the corresponding nitro- α,β -unsaturated ester (XVII). The cyclic ester (VI) has the *m*-nitrophenyl adduct added to it to become the 6(R)-olefin
20 (XXV), see EXAMPLE 16, which is hydrogenated with the appropriate catalyst to produce the reduced compound, the nitro- α,β -unsaturated ester (XVII), see EXAMPLE 17. The nitro- α,β -unsaturated ester (XVII) is then transformed to the protease inhibitor (XIX) as previously discussed.

CHART G discloses a process to produce optically pure hydroxy lactones of
25 formula (CVI). The process for the transformation of the salt of the formula (CIV) to the hydroxy lactone of formula (CVI) follows EXAMPLES 1 thru 4 and 18. The hydroxyl and amino groups of the starting material (CI) can be protected as is well known to those skilled in the art. These protecting groups can be removed at various places in the subsequent process steps, by means well known to those skilled
30 in the art, or carried on thru to the product where they would be removed to produce the desired product. It is apparent to one skilled in the art there are numerous ways to produce the optically pure (CIV). It is not important how the resolution of EXAMPLE 3 producing the optically pure (CIV) is performed. The invention here is the conversion of the optically pure (CIV) to the optically pure (CVI).

35 The acid (III) forms base addition salts when reacted with bases of sufficient strength. The pharmaceutically acceptable salts include both inorganic and organic

bases. The pharmaceutically salts are preferred over the free acids since they produce compounds which are more water soluble and more crystalline. The preferred pharmaceutically acceptable salts include salts of the following bases, for example, hydroxide, ammonia, tromethamine (THAM), 2-amino-2-(hydroxymethyl)-1,3-propanediol, (1R,2S)-norephedrine, (1S,2R)-norephedrine, (R)-2-amino-2-phenylethanol, (S)-2-amino-2-phenylethanol, (R)-1-phenylethylamine and (S)-1-phenylethylamine. It is preferred that the salt be the (1R,2S)-norephedrine salt.

[R-(R*,R*)]-N-[3-[1-[5,6-Dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide (XIX) the compound of EXAMPLE 15 (COMPOUND) is known to be useful in treating humans infected with HIV, see International Publications WO95/30670 and WO94/11361. This COMPOUND inhibits retroviral proteinases and thus inhibit the replication of the virus. The COMPOUND of the present invention is useful in inhibiting human retroviral protease. The COMPOUND is useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-1 or HIV-2) or human T-cell leukemia viruses (HTLV-I or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and/or related diseases.

Patients to be treated would be those individuals (1) infected with one or more strains of a human retrovirus as determined by the presence of either measurable viral antibody or antigen in the serum and (2) in the case of HIV, having either an asymptomatic HIV infection or a symptomatic AIDS defining infection such as (a) disseminated histoplasmosis, (b) isopsoriasis, (c) bronchial and pulmonary candidiasis including pneumocystic pneumonia (d) non-Hodgkin's lymphoma or (e) Kaposi's sarcoma and being less than sixty years old; or having an absolute CD4+ lymphocyte count of less than 500/mm³ in the peripheral blood. Treatment would consist of maintaining an inhibitory level of the COMPOUND according to this invention in the patient at all times.

The COMPOUND of the present invention is useful for treating patients infected with human immunodeficiency virus (HIV) which results in acquired immunodeficiency syndrome (AIDS) and related diseases. For this indication, these compounds may be administered by oral, intranasal, transdermal, subcutaneous and parenteral (including intramuscular and intravenous) routes in doses of 0.1 mg to 100 mg/kg of body weight per day. It is preferred that the ccc be administered orally.

Those skilled in the art would know how to formulate the COMPOUND into appropriate pharmaceutical dosage forms. Examples of the dosage forms include

oral formulations, such as tablets or capsules. or parenteral formulations, such as sterile solutions.

When the compound in this invention is administered orally, an effective amount is from about 0.1 mg to about 100 mg per kg of body weight per day. It is preferred that the effective amount is from about 10 to about 100 mg per kg of body weight per day. It is more preferred that the amount be from about 30 mg to about 90 mg per kg of body weight. It is preferred that the compound be administered 2 to 5 times daily, more preferably 3 times daily. It is preferred that the dose be from about 2,700 mg/day to about 4,500 mg/day.

10 Either solid or fluid dosage forms can be prepared for oral administration. It is preferred the compound be given in solid dosage form, more preferably as a capsule.

When the compounds of this invention are administered parenterally, they can be given by injection or by intravenous infusion. An effective amount is from about 0.1 mg to 100 mg per kg of body weight per day. Parenteral solutions are prepared by dissolving the compounds of this invention in aqueous vehicle and filter sterilizing the solution before placing in a suitable sealable vial or ampule. Parenteral suspensions are prepared in substantially the same way except a sterile suspension vehicle is used and the compounds of this invention are sterilized with ethylene oxide or suitable gas before it is suspended in the vehicle.

20 The exact route of administration, dose, or frequency of administration would be readily determined by those skilled in the art and is dependant on the age, weight, general physical condition and/or other clinical symptoms specific to the patient to be treated.

DEFINITIONS AND CONVENTIONS

25 The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims.

DEFINITIONS

All temperatures are in degrees Centigrade.

TLC refers to thin-layer chromatography.

30 HPLC refers to high pressure liquid chromatography; 4.6 x 250 mm Zorbax C-8 column, mobile phase A = methanol, mobile phase B = 6.5 g *t*-butyl ammonium hydroxide in water, pH to 4.0 with acetic acid, gradient from 65/35 A/B to 70/30 A/B over 20 min, then isocratic 70/30 A/B for 5 min, then gradient to 90/10 A/B over 20 min; flow rate is 1.0 ml/min; UV detection at 254 nm.

35 THF refers to tetrahydrofuran.

DMF refers to dimethylformamide.

MTBE refers to methyl *t*-butyl ether.

DMSO refers to dimethylsulfoxide.

Saline refers to a saturated aqueous sodium chloride solution.

Chromatography (column and flash chromatography) refers to
5 purification/separation of compounds expressed as (support, eluent). It is understood
that the appropriate fractions are pooled and concentrated to give the desired
compound(s).

CMR refers to C-13 magnetic resonance spectroscopy, chemical shifts are
reported in ppm (δ) downfield from TMS.

10 NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical
shifts are reported in ppm (δ) downfield from tetramethylsilane.

MS refers to mass spectrometry expressed as m/e , m/z or mass/charge unit.
[M + H]⁺ refers to the positive ion of a parent plus a hydrogen atom. EI refers to
electron impact. CI refers to chemical ionization. FAB refers to fast atom
15 bombardment.

Ether refers to diethyl ether.

Pharmaceutically acceptable refers to those properties and/or substances
which are acceptable to the patient from a pharmacological/toxicological point of
view and to the manufacturing pharmaceutical chemist from a physical/chemical
20 point of view regarding composition, formulation, stability, patient acceptance and
bioavailability.

When solvent pairs are used, the ratios of solvents used are volume/volume
(v/v).

When the solubility of a solid in a solvent is used the ratio of the solid to the
25 solvent is weight/volume (wt/v).

COMPOUND refers to [R-(R*,R*)]-N-[3-[1-[5,6-dihydro-4-hydroxy-2-oxo-6-(2-
phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-
pyridinesulfonamide (XIX).

Alkyl refers to C₁-C₄ alkyl including both straight and branched chain
30 isomers.

W₁ refers to ethyl and *t*-butyl.

EXAMPLES

Without further elaboration, it is believed that one skilled in the art can,
using the preceding description, practice the present invention to its fullest extent.
35 The following detailed examples describe how to prepare the various compounds
and/or perform the various processes of the invention and are to be construed as

merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.

5 PREPARATION 1 Resolution Of (+)-1-(3-nitrophenyl)propanol (XX) By Conversion To (S)-1-(3-nitrophenyl)propanol (XXI) and (R)-1-(3-nitrophenyl)propanol acetate

Celite supported PS-30 lipase (Amano, 24 g) and isopropenylacetate (22.00 ml, 0.20 mol) is added to (+)-1-(3-nitrophenyl)propanol (XX, 24.00 g, 0.13 mol) in
10 MTBE (240 mL). The mixture is stirred at 20-25° for 2 days. At the end of this time the catalyst is removed by filtration, the catalyst cake washed with ether, and the the mixture concentrated under reduced pressure to give an acetate-alcohol mixture. Separation of the mixture by silica gel chromatography gives (R)-1-(3-nitrophenyl)propanol acetate (13.03 g), $[\alpha]_D = +68.7^\circ$ (ethanol, c = 1) and
15 (S)-1-(3-nitrophenyl)propanol (10.7 g), $[\alpha]_D = -33.0^\circ$ (ethanol, c = 1).

PREPARATION 2 (S)-1-(3-nitrophenyl)propanol mesylate (XXII)

Diisopropylethylamine (1.07 g, 8.3 mmol) is added to a mixture of (S)-1-(3-nitrophenyl)propanol (XXI, PREPARATION 1, 1 g, 5.5 mmol) in methylene chloride (20 mL). The mixture is cooled to -20° and methanesulfonyl chloride (0.69 g, 6.02
20 mmol) is added. The reaction is held at -20° for 10 min, then held at 0° for 40 min. The reaction is diluted with methylene chloride, sodium bicarbonate (5%) is added and the phases are separated. The methylene chloride is evaporated to give the title compound, $[\alpha]_D = -79.9^\circ$ (ethanol, c = 1); TLC (silica gel GF, ethyl acetate/hexane, 20/80) $R_f = 0.19$; NMR ($CDCl_3$, TMS) 0.96 - 1.01, 1.88 - 2.17, 2.89, 5.54 - 5.59, 7.57 -
25 7.62, 7.70 - 7.73 and 8.20 - 8.24 δ .

PREPARATION 3 (S)-Dimethyl 1-[1-(3-nitrophenyl)propyl]malonate (XXIII)

A solution of sodium ethoxide (1.0 M) is prepared by dissolving sodium metal (1.27 g, 0.055 mol) in absolute ethanol (55 mL). Diethyl malonate (8.84 g, 0.055 mol) is added to the above solution at 0°. (S)-1-(3-nitrophenyl)propanol mesylate
30 (XXII, PREPARATION 2, 1.43 g, 5.5 mmol) is added dropwise to the above solution of sodium malonate (6.4 mL, 6.4 mmol) at -20°. After 2 hr at 20-25°, an additional aliquot of sodium malonate (5 mL, 5.0 mmol) is added to the reaction and then stirred overnight at 20-25°. The reaction is concentrated and partitioned between ethyl acetate and hydrochloric acid (1 N). The organic phase is separated and the
35 solvent removed to give crude product which is chromatographed (silica gel; ethyl acetate/hexane, 10/90) to give the title compound, $[\alpha]_D = +19.4^\circ$ (ethanol, c = 1); TLC

(silica gel GF, ethyl acetate/hexane, 20/80) $R_f = 0.48$; NMR (CDCl_3 , TMS) 0.70 - 0.75, 0.96 - 1.00, 1.27 - 1.32, 1.56 - 1.88, 3.37 - 3.45, 3.65 - 3.69, 3.86 - 3.96, 4.21 - 4.28, 7.44 - 7.49, 7.54 - 7.57 and 8.08 - 8.11 δ .

PREPARATION 4 (S)-3-(3-Nitrophenyl)pentanoic Acid (XXIV)

- 5 (S)-Dimethyl 1-[1-(3-nitrophenyl)propyl]malonate (XXIII, PREPARATION 3, 0.73 g, 2.26 mmol) is refluxed in hydrochloric acid (6 N, 10 mL) for 18 hr. The reaction is cooled and extracted with ethyl acetate. The ethyl acetate phase is washed with water, separated and condensed to give the title compound, $[\alpha]_D = 13.3^\circ$ (methanol, $c = 1$); TLC (silica gel GF, acetic acid/ethyl acetate/hexane, 2/20/80) $R_f = 0.46$; NMR (CDCl_3 , TMS) 0.78 - 0.83, 1.59 - 1.82, 2.59 - 2.78, 3.07 - 3.17, 7.44 - 7.54 and 8.04 - 8.10 δ .
- 10

PREPARATION 5 (+)-3-(3-Nitrophenyl)pentanoic acid methyl ester (XIII)

- To a solution of (+)-3-(3-nitrophenyl)pentanoic acid (XXIV, 30.21 g, 135 mmol) in methanol (250 mL) is added concentrated sulfuric acid (0.6 mL). The resulting mixture is heated to reflux for 3 hours. Upon cooling, the mixture is partitioned between ethyl acetate and sodium bicarbonate (5% aqueous). The aqueous layer is separated and back-extracted with two additional portions of ethyl acetate. The combined organic phases are washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered and concentrated to give the title compound, TLC (silica gel GF) for acetic acid/ethyl acetate/hexane (2/20/80) $R_f = 0.54$, for ethyl acetate/hexane (20/80) $R_f = 0.54$; NMR (CDCl_3 , TMS) 0.80, 1.56-1.83, 2.55-2.75, 3.05-3.2, 3.57, 7.4-7.55 and 8.03-8.12 δ .
- 15
- 20

PREPARATION 6 (S)-3-(3-Nitrophenyl)pentanoic acid methyl ester (XIII)

- Following the general procedure of PREPARATION 5 and making non-critical variations but starting with (S)-3-(3-nitrophenyl)pentanoic Acid (XXIV, PREPARATION 4) the title compound is obtained.
- 25

EXAMPLE 1 Ethyl-3-hydroxy-3-(2-phenylethyl)hexanoate (II)

- To a solution of diisopropylamine (32.2 mL, 230 mmol) in tetrahydrofuran (240 mL) at -58° is added 2.63 M n-butyl lithium in hexane (87.4 mL, 230 mmol) over one hour. Ethyl acetate (21.4 mL, 220 mmol) is then added and the reaction mixture stirred for 1 hour during which time the reaction mixture was cooled to -70° . 1-Phenyl-3-hexanone (I, 35.2 g, 200 mmol) is added slowly over 30 minutes and the reaction mixture stirred cold for 1 hour. The mixture was quenched with aqueous ammonium chloride (100 mL) and warmed to $20-25^\circ$. The mixture is then acidified with hydrochloric acid (4 M). The desired product is extracted into methyl *t*-butyl ether dried over magnesium sulfate and concentrated to give the title compound,
- 30
- 35

TLC R_f = 0.71 (ethyl acetate/hexane, 30/70); NMR (CDCl_3) 7.28-7.12, 4.13, 3.60, 2.73-2.63, 2.50, 1.83-1.77, 1.58-1.53, 1.41-1.36, 1.24 and 0.93 δ ; CMR (CDCl_3) 173.0, 143.2, 128.5, 128.4, 128.3, 128.1, 125.8, 72.8, 60.6, 42.9, 41.3, 30.1, 17.0, 14.6 and 14.2 δ ; MS (CI, ammonia) m/z (relative intensity) 282 (100), 264 (63), 247 (10), 194 (13), 172 (5), 159 (5).

EXAMPLE 2 3-Hydroxy-3-(2-phenylethyl)hexanoic acid (III)

Ethyl-3-hydroxy-3-(2-phenylethyl)hexanoate (II, EXAMPLE 1, 200 mmol) is dissolved in methanol (423 ml) and 2M sodium hydroxide (150 ml, 300 mmol) is added. The reaction mixture is stirred at 20-25° overnight. Methanol is removed and the remaining aqueous mixture is acidified with hydrochloric acid (4 M). The desired product is extracted into methyl *t*-butyl ether and dried over magnesium sulfate. The product is concentrated to give the title compound, TLC R_f = 0.10 (ethyl acetate/hexane, 30/70); NMR (CDCl_3) 7.43-7.13, 2.77-2.62, 2.06, 1.87-1.76, 1.63-1.57, 1.45-1.31 and 0.93 δ ; CMR (CDCl_3) 176.9, 141.9, 128.4, 128.3, 125.9, 73.4, 42.7, 41.4, 40.9, 31.9, 17.0 and 14.5 δ ; MS (CI, ammonia) m/z (relative intensity) 254 (100), 236 (28), 218 (3), 194 (3), 159 (5).

EXAMPLE 3 (R)-3-Hydroxy-3-(2-phenylethyl)hexanoic acid, (1R,2S)-norephedrine salt (IV)

3-Hydroxy-3-(2-phenylethyl)hexanoic acid (III, EXAMPLE 2, 2.83 g, 11.97 mmol adjusted for methyl *t*-butyl ether) is dissolved in acetonitrile (15 ml). (1R,2S)-Norephedrine (910 mg, 5.99 mmol, 0.5 equiv.) is added and the mixture stirred overnight at 20-25°. After approximately one hour, the product began to precipitate. The following morning the slurry was cooled to 0° for 1 hour before filtering to collect the hydroxyacid salt. The cake is washed with acetonitrile (9 ml cold) and dried under reduced pressure with heat to give the desired product.

This material (ca. 1.5 g) is slurried in acetonitrile (21 ml) and heated to 70° for 30 minutes. The resulting solution is gradually cooled to 20-25° as the product precipitates. After 2 hours at 20-25°, the product is collected by vacuum filtration, washed with acetonitrile (21 ml) and dried at 20-25° under reduced pressure.

Again, this material is slurried in acetonitrile (21 ml) and heated to 70° for 30 minutes. The resulting solution is gradually cooled to room 20-25° as the product precipitates. After 2 hours at 20-25°, the product is collected by vacuum filtration, washed with acetonitrile (21 ml) and dried at 20-25° under reduced pressure to give the title compound, mp = 113-117°; NMR (methanol) 7.41-7.08, 5.18, 4.98, 3.15, 2.65-2.60, 2.34, 1.79-1.73, 1.56-1.52, 1.43-1.37, 1.06 and 0.92 δ ; CMR (methanol) 181.4, 144.6, 142.2, 130.2-129.3, 127.6, 127.1, 74.5, 73.9, 54.0, 46.4, 43.6, 43.4, 31.9, 31.9,

18.6, 15.7 and 12.9 δ ; MS (CI, ammonia) m/z (relative intensity) 388 (25), 303 (15), 254 (30), 236 (7), 152 (100); $[\alpha]_D^{25} = 16$ ($C = 1.0$, methanol).

EXAMPLE 4 (6R)-5,6-dihydro-4-hydroxy-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (VI)

5 (R)-3-Hydroxy-3-(2-phenylethyl)hexanoic acid, (1R,2S)-norephedrine salt (IV, EXAMPLE 3, 81 g, 209 mmol) is converted to the free acid, (R)-3-hydroxy-3-(2-phenylethyl)hexanoic acid by slurrying the salt in ethyl acetate (810 ml) and adding hydrochloric acid (1 M, 810 ml). The free acid is extracted into the ethyl acetate and the ethyl acetate layer collected and concentrated to an oil. The free acid is
10 then redissolved in tetrahydrofuran (490 ml) and the solution cooled to -10° . Carbonyl-diimidazole (37.3 g, 230 mmol) is added and the reaction mixture stirred cold for 2 hours. Monoethyl malonate magnesium salt (65.9 g, 230 mmol) is added and the reaction mixture gradually warmed to $20-25^\circ$ while stirring overnight. The reaction is quenched with hydrochloric acid (1 M, 490 ml) and the organic layer
15 collected. The organic layer is washed with a sodium bicarbonate solution and concentrated to 294 ml containing (R)-ethyl 5-hydroxy-7-phenyl-5-propylheptanoate (V). A solution of sodium hydroxide (0.5 M, 460 ml, 230 mmol) is added to the concentrated solution and the resulting cloudy mixture stirred at $20-25^\circ$ overnight. Methyl *t*-butyl ether is added and the aqueous layer collected. The aqueous phase is
20 acidified with hydrochloric acid (4 M) and the product is extracted into methyl *t*-butyl ether. The methyl *t*-butyl ether layer is dried over sodium sulfate and concentrated to give the title compound, TLC $R_f = 0.22$ (ethyl acetate/hexane, 50/50); NMR ($CDCl_3$) 7.29-7.13, 3.39, 2.70, 2.71-2.62, 1.98-1.93, 1.74-1.66, 1.45-1.34 and 0.93 δ ; CMR ($CDCl_3$) 176.89, 167.5, 140.4, 128.6, 128.4, 128.2, 128.2, 126.3, 83.2, 60.1,
25 47.1, 44.3, 40.7, 40.4, 29.6, 16.8 and 14.5 δ ; MS (CI, ammonia) m/z (relative intensity) 278 (100), 254 (15), 236 (15), 217 (5), 195 (5), 159 (3).

EXAMPLE 5 (4-Phenylphenoxy)(4-chlorothiophenoxy)methane (VIII)

To a slurry of paraformaldehyde (36.24 g, 1.21 mol, 1.58 equiv) in toluene (243 ml) at 22° is added aqueous hydrobromic acid (48.5 wt%, 652 ml, 5.86 mol, 7.68
30 equiv) with an endotherm to 18° . The resultant biphasic solution is warmed to 40° and a solution of 4-chlorothiophenol (VII, 138.81 g, 0.960 mol, 1.26 equiv) in toluene (116 ml) is added over 1/2 hour while maintaining $40-43^\circ$ and rinsed in with toluene (50 ml). The mixture is then warmed to 50° and stirred 1 hour. The mixture is cooled to 10° , the phases separated, and the aqueous washed with toluene (250 ml).
35 The combined organics are treated with ice water (500 ml), hexanes (350 ml) and the phases separated. The aqueous phase is then washed with toluene (200 ml) and

the combined organic phases are dried over magnesium sulfate and concentrated to give crude bromomethylthio-4-chlorobenzene (268.01 g), NMR 7.43, 7.34, 4.79 δ ; CMR 134.37, 132.05, 131.78, 129.46, 37.32 δ ; HRMS (EI⁺) calculated for C₇H₆BrClS = 235.9063, found = 235.9063.

5 To a solution of 4-phenylphenol (129.91 g, 0.763 mol, 1.00 equiv) in DMF (400 ml) at -10° is added a solution of potassium t-butoxide in THF (20 wt%, 429.40 g, 0.765 mol, 1.00 equiv) followed by THF (50 ml), while maintaining less than 5°. The mixture is concentrated to 557 g net weight and DMF (33 ml) added followed by the crude bromomethylthio-4-chlorobenzene prepared above with a free exotherm from
10 22° to 70°. The crude bromomethylthio-4-chlorobenzene is rinsed in with DMF (50 ml) and the resultant slurry stirred at 80° for 1/2 hour. The mixture is cooled to 22° and hexanes (400 ml) followed by water (500 ml) added. The precipitate is collected by vacuum filtration and washed with water (1500 ml) and methanol (300 ml) and dried in a nitrogen stream to give a solid (251.25 g). The solid is dissolved in
15 methylene chloride (1 l) and dried over magnesium sulfate and washed with methylene chloride (200 ml). A constant volume concentration (1300-1800 ml) is then performed while adding a total of 1.35 l methanol and ending at 1344 g net weight. The resultant precipitate is collected at 20-25° by vacuum filtration, washed with methanol (1 l) and dried at 65° under reduced pressure to give the title
20 compound, mp = 99-101°; TLC (*R_f* = 0.64, ethyl acetate/hexanes, 1/9); HPLC (rt) = 9.67 min; NMR (CDCl₃) 7.55-6.99 and 5.44 δ ; CMR (CDCl₃) 155.99, 140.52, 135.28, 133.48, 132.06, 129.18, 128.75, 128.24, 126.90, 126.80, 116.34, 73.15 δ ; MS (CI, NH₃) *m/z* (relative intensity) 346 (1.7), 344 (3.5), 328 (3.8), 326 (8.1), 201 (11), 200 (100).

EXAMPLE 6 1-Chloromethoxy-4-phenylbenzene (IX)

25 To a mixture of (4-phenylphenoxy)(4-chlorothiophenoxy)methane (VIII, (EXAMPLE 5, 176.45 g, 539.9 mmol) in methylene chloride (750 ml) at 21° is added a solution of sulfonyl chloride (73.32 g, 543.2 mmol, 1.01 equiv) in methylene chloride (150 ml) while maintaining < 23° over 8 min. The mixture is stirred at 20° for 11 min then cooled to 3°. A mixture of cyclohexene (60.7 ml, 599 mmol, 1.11
30 equiv) in methylene chloride (100 ml) is added over 10 min at 3-5°, then warmed to 19° and stirred 10 min. The mixture is concentrated to 600 ml total volume and hexanes (500 ml) added. The mixture is concentrated to 500 ml and hexanes (300 ml) added. The resultant slurry is concentrated to 500 ml and pentane (1.3 l) added. The slurry is cooled to -50° and the precipitate collected by vacuum filtration and
35 washed with -30° pentane (700 ml) and dried to give a solid (115.28 g). A portion (110.34 g) of the solid is dissolved in methylene chloride (200 ml). Hexanes (1 l) is

added and the mixture concentrated to 949 g. Hexane (200 ml) is added and the mixture concentrated to 589 g. Hexane (500 ml) is added, the slurry cooled to -30°, the precipitate collected by vacuum filtration, washed with hexane (300 ml) and dried to give the title compound, mp 67-70°; TLC R_f = 0.68 (ethyl acetate/hexanes, 8/92); HPLC rt = 6.45 min; NMR 7.80-7.13 and 5.89 δ ; CMR (CDCl₃) 155.03, 140.34, 136.49, 128.78, 128.35, 127.10, 126.88, 116.39 and 77.16 δ ; HRMS (EI⁺) calculated for C₁₃H₁₁ClO = 218.0498, found = 218.0493.

EXAMPLE 7 (R)-(4-phenylphenoxy)methyl-3-(2-phenylethyl)-3-[(4-phenylphenoxy)methoxy]hexanoate (X)

To a slurry of (R)-3-hydroxy-3-(2-phenylethyl)hexanoic acid (-)-norephedrine salt (IV, EXAMPLE 4, 25.04 g, 64.62 mmol) in water (185 ml) and MTBE (185 ml) at 20-25° is added aqueous hydrochloric acid (37.5 wt%, 7.51g, 77.24 mmol, 1.20 equiv), adjusting the pH from 8.04 to 1.30. The phases are separated and the aqueous phase is washed with MTBE (185 ml). The organic phases are dried over magnesium sulfate and concentrated. To the concentrate is then added toluene (77 ml), N,N-diisopropylethylamine (96 ml, 551 mmol, 8.53 equiv), and 1-chloromethoxy-4-phenylbenzene (IX, EXAMPLE 6, 71.88 g, 328.68 mmol, 5.09 equiv). The mixture is then warmed to 110° and stirred at 110-117° for 5 hrs. The mixture is cooled to 65° and methanol (800 ml) added. The resultant slurry is cooled to -30° and the product collected by vacuum filtration, washed with methanol (200 ml) and dried to give crude product. An analytical sample is obtained by chromatography (ethyl acetate/hexanes) followed by crystallization to give the title compound, mp = 104.0-105.5°; TLC R_f = 0.50 (15% ethyl acetate/hexanes); HPLC rt = 13.8 min; NMR (CDCl₃) 7.51-7.04, 5.78, 5.32, 2.75, 2.64-2.58, 2.03-1.97, 1.78-1.72, 1.41-1.28 and 0.86 δ ; CMR (CDCl₃) 169.38, 157.14, 156.14, 142.04, 140.71, 140.41, 135.85, 134.56, 128.75, 128.68, 128.35, 128.29, 128.09, 126.97, 126.81, 126.73, 125.78, 116.13, 87.34, 85.20, 80.40, 41.19, 38.80, 38.61, 29.73, 16.74, 14.35 δ ; MS (CI, NH₃) m/z (relative intensity) 620 (1.7), 619 (7.8), 618 (19), 418 (13), 266 (100); $[\alpha]_D^{25}$ = -4 (C = 1.0, methylene chloride).

EXAMPLE 8 (R)-3-(2-phenylethyl)-3-[(4-phenylphenoxy)methoxy]hexanol (XI)

To a slurry of crude (R)-(4-phenylphenoxy)methyl-3-(2-phenylethyl)-3-[(4-phenylphenoxy)methoxy]hexanoate (X, EXAMPLE 7, 56.5 wt%, 49.32 g, 46.38 mmol) in toluene (500 ml) is added a solution of diisobutylaluminum hydride in toluene (1.52 M, 85 ml, 129.2 mmol, 2.79 equiv) while maintaining -20°. The mixture is slowly warmed to 1° over 2.5 hrs, then stirred 1/2 hr. Acetone (8.0 ml, 108.5 mmol, 2.34 equiv) is added and the mixture cannulated into an 18° solution of

citric acid monohydrate (136 g, 647.2 mmol, 14.0 equiv) in water (433 ml) with controlled exotherm to 28°, rinsing with toluene (100 ml). The mixture is stirred at 20-25° for 1.5 hrs and the insolubles removed by vacuum filtration, washing with toluene. The phases are separated in the filtrate and the aqueous phase is washed with toluene (2 x 300 ml). The organic phases are dried over magnesium sulfate, then washed with aqueous sodium hydroxide (0.5 M, 2 x 500 ml). The organic phases are concentrated to 137 g net weight and methanol (250ml) is added. The resultant slurry is concentrated and methanol (250 ml) is added. The mixture is again concentrated and methanol (250 ml) added. The slurry is cooled to -60° and the insolubles removed by filtration. The filtrate is concentrated 60 g net weight, hexane (500 ml) is added, and the mixture concentrated to 22 g net weight. Hexane (500 ml) is added and the mixture again concentrated to 40 g net weight. Methylene chloride (25 ml) is added followed by a slow addition of hexane (500 ml) and pentane (250 ml) with cooling to -55°. The product is collected by vacuum filtration, washed with pentane (200 ml) and dried in a nitrogen stream to give the desired product. An analytical sample is obtained by chromatography (ethyl acetate/hexane) followed by crystallization (methylene chloride/ hexane) to give the title compound, mp = 49-53°; TLC R_f = 0.14 (15% ethyl acetate/hexane); HPLC r_t = 9.18 min; NMR ($CDCl_3$) 7.56-7.07, 5.36, 3.76-3.74, 2.63-2.58, 1.94-1.88, 1.70-1.65, 1.38-1.30, 0.93 δ ; CMR ($CDCl_3$) 157.05, 142.25, 140.73, 134.68, 128.70, 128.42, 128.29, 128.21, 126.76, 125.85, 116.07, 87.05, 81.85, 58.89, 38.77, 38.60, 38.23, 29.90, 17.04, 14.62 δ ; MS (CI, NH_3) m/z (relative intensity) 423 (2.3), 422 (9.9), 252 (100); $[\alpha]_D^{25}$ = 6 (C = 1.0, methylene chloride).

EXAMPLE 9 (R)-3-(2-phenylethyl)-3-[(4-phenylphenoxy)methoxy]hexanol
(XII)

To a mixture of crude (R)-3-(2-phenylethyl)-3-[(4-phenylphenoxy)methoxy]hexanol (XI, EXAMPLE 8, 91.1 wt%, 15.40 g, 34.68 mmol) in methylene chloride (47 ml) at 0° is added a solution of potassium bromide (0.4057 g, 3.409 mmol, 0.098 equiv) and sodium bicarbonate (1.557 g, 18.53 mmol, 0.53 equiv) in water (20.5 ml) followed by 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy, free radical (0.3060 g, 1.776 mmol, 0.051 equiv). Aqueous sodium hypochlorite (13.4 wt%/vol, 26.6 ml, 47.88 mmol, 1.38 equiv) is then added by syringe pump over 1 hr while maintaining 1-5°. A solution of sodium thiosulfate pentahydrate (0.5182 g, 2.088 mmol, 0.0602 equiv) in water (14 ml) is then added. The phases are separated at 0° and the aqueous phase is washed with 2 x 50 ml methylene chloride. The organic phases are immediately filtered through magnesol (50.25 g) and rinsed

through with methylene chloride (400 ml). The extracts are concentrated to an oil (30 g) and hexane (500 ml) is added. The mixture is concentrated to 250 g net weight and hexane (100 ml) added. The mixture is concentrated to 186 g net weight and pentane (300 ml) added. The resultant slurry is cooled to -50° and the desired
 5 product collected by vacuum filtration, washed with -50° pentane (100 ml) and dried to give a solid, analytically pure to give the title compound, mp = 47.0-48.5°; TLC R_f = 0.41 (ethyl acetate/hexane, 10/90); HPLC rt = 10.95 min; NMR (CDCl₃) 9.79, 7.53, 7.40, 7.26, 7.20-7.08, 5.40, 2.67, 2.65-2.56, 1.99, 1.76, 1.38, 0.93 δ; CMR (CDCl₃) 201.83, 156.90, 141.69, 140.68, 134.82, 128.72, 128.47, 128.29, 128.24, 126.77,
 10 125.99, 116.03, 87.19, 80.36, 50.14, 39.21, 39.14, 29.74, 16.86, 14.45 δ; MS (CI, NH₃) m/z (relative intensity) 420 (3.5), 220 (100); $[\alpha]_D^{25} = 14$ (C = 1.0, methylene chloride).

EXAMPLE 10 (3S),(7R) 4-Carbomethoxy-3-(3-nitrophenyl)-7-(2-phenylethyl)-7-
 [(4-phenylphenoxy)methoxy]decan-5-ol (mixture of
 15 diastereomers at C-4 and C-5) (XIV)

To a mixture of (S)-methyl 3-(3-nitrophenyl)pentanoate also known as (S)-3-(3-Nitrophenyl)pentanoic acid methyl ester (XIII, PREPARATION 6, 3.78 g, 15.932 mmol) in THF (55 ml) at -80°, is added a solution of sodium hexamethyldisilazide in THF (0.935 M, 17.5 ml, 16.36 mmol, 1.027 equiv) over 7 min while maintaining -80
 20 to -85°. The resultant mixture is then warmed to -74° and stirred at -74 to -76° for 18 min. The mixture is cooled to -90° and a solution of (R)-3-(2-phenylethyl)-3-[(4-phenylphenoxy)methoxy]hexanal (XII, EXAMPLE 9, 6.50 g, 16.147 mmol, 1.013 equiv) in THF is added over 10 min while maintaining -85 to -90°, and rinsed in with THF (20 ml). The mixture is then warmed to -71° and saturated aqueous
 25 ammonium chloride solution (90 ml) added, followed by water (90 ml) and MTBE (90 ml) and the mixture warmed to 20-25°. The phases are separated and the aqueous washed with MTBE (90 ml). The extracts are dried over magnesium sulfate, and concentrated to an oil. An analytical sample is obtained by chromatography (ethyl acetate/hexanes) to give the title compound, TLC R_f = 0.16, 0.24 (ethyl
 30 acetate/hexanes, 10/90); HPLC rt = 12.52, 12.68, 12.97 min; MS (electrospray, sodium acetate) m/z (relative intensity) 662.5 (100).

EXAMPLE 11 (3S),(7R) 4-Carbomethoxy-3-(3-nitrophenyl)-7-(2-phenylethyl)-7-
 [(4-phenylphenoxy)methoxy]decan-5-one (mixture of
 35 diastereomers at C-4)

A solution of (3S),(7R) 4-carbomethoxy-3-(3-nitrophenyl)-7-(2-phenylethyl)-7-
 [(4-phenylphenoxy)methoxy]decan-5-ol (XIV, EXAMPLE 10, 11.12 g, 79.0 wt%,

13.73 mmol) in methylene chloride (530 ml) is added to a ground mixture of pyridinium chlorochromate (16.099 g, 74.685 mmol, 5.44 eq), sodium acetate (6.984 g, 85.14 mmol, 6.20 eq) and florisil (5.181 g) while maintaining less than 11°. The mixture is warmed to 21° and stirred at 20-25° for 20 hrs. The resultant slurry is
5 filtered through magnesol (47.7 g) and rinsed with methylene chloride (375 ml). The filtrate is concentrated to an oil. An analytical sample of the title compound is obtained by chromatography (ethyl acetate/ hexanes): TLC R_f = 0.34 (ethyl acetate/hexanes, 10/90); HPLC rt = 13.02, 13.23 min; NMR (CDCl_3) 8.05-8.01, 7.60-7.00, 5.37, 5.21, 4.03, 3.94, 3.75, 3.58-3.43, 3.39, 2.96, 2.78-1.37, 1.20, 0.91, 0.71-0.61
10 δ ; CMR (CDCl_3) 200.89, 200.60, 168.29, 167.81, 157.10, 157.05, 148.38, 148.30, 143.58, 143.32, 141.99, 141.93, 140.73, 140.69, 135.29, 135.01, 134.78, 129.38, 129.23, 128.75, 128.45, 128.36, 128.23, 126.77, 125.91, 125.80, 122.96, 122.80, 122.04, 122.00, 116.16, 87.14, 86.92, 80.93, 80.44, 66.34, 65.92, 52.79, 52.35, 49.02, 48.62, 46.28, 46.20, 38.70, 38.51, 38.43, 37.99, 30.10, 29.52, 26.92, 26.71, 16.64,
15 16.39, 14.39, 14.16, 11.81, 11.58; MS (CI, ammonia) m/z (relative intensity) 656 (2.8), 655 (6.1), 136 (100).

EXAMPLE 12 (3S),(7R) 4-carbomethoxy-7-hydroxy-3-(3-nitrophenyl)-7-(2-phenylethyl)-decan-5-one (mixture of diastereomers at C-4)
(XVI)

20 To a mixture of (3S),(7R) 4-carbomethoxy-3-(3-nitrophenyl)-7-(2-phenylethyl)-7-[(4-phenylphenoxy)methoxy]decan-5-one (XV, EXAMPLE 11, 9.14 g, 83.7 wt%, 11.995 mmol) in THF (20 ml) at 23° is added a solution of sulfuric acid in methanol (0.524 M, 20 ml, 10.48 mmol, 0.87 eq). The mixture is allowed to stand at 23° for 22 hrs, then a solution of sodium bicarbonate (3.52 g, 41.90 mmol, 3.49 eq) in water (50
25 ml) is added, followed by MTBE (50 ml). The phases are separated and the aqueous is washed with MTBE (30 ml). The combined organics are washed with aqueous sodium hydroxide (0.5 M, 2 x 50 ml) at 5°, then water (2 x 10 ml), then twice with a mixture of saturated aqueous ammonium chloride (15 ml) and water (35 ml). The organics are dried on magnesium sulfate and concentrated to an oil. An analytical
30 sample of the title compounds is obtained by chromatography (ethyl acetate/hexanes): TLC R_f = 0.39 (ethyl acetate/hexanes, 25/75); HPLC rt = 8.15, 8.50 min; NMR (CDCl_3) 8.15-7.85, 7.48-7.01, 3.99, 3.92, 3.78, 3.50-3.39, 3.38, 3.32-1.21, 0.82 and 0.74-0.67 δ ; CMR (CDCl_3) 205.20, 204.99, 168.00, 167.46, 148.38, 143.10, 142.04, 141.97, 135.23, 134.99, 129.47, 129.33, 128.46, 128.41, 128.28,
35 128.18, 125.85, 122.82, 122.58, 122.17, 73.83, 73.49, 66.63, 66.36, 52.92, 52.50, 50.79, 50.60, 46.25, 46.17, 41.57, 41.01, 40.83, 30.03, 29.60, 26.95, 17.05, 16.90, 14.55,

14.43, 11.74 and 11.47 δ .

EXAMPLE 13 [3 α (R),6(R)]5,6-dihydro-4-hydroxy-3-[1-(3-nitrophenyl)propyl]-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (XVII)

A 4° solution of aqueous sodium hydroxide (1 M, 11.4 ml, 11.4 mmol, 1.89 equiv) in methanol (35 ml) is added to crude (3S),(7R) 4-carbomethoxy-7-hydroxy-3-(3-nitrophenyl)-7-(2-phenylethyl)-decan-5-one (mixture of diastereomers at C-4) (XVI, EXAMPLE 12, 73.3 wt%, 3.740 g, 6.018 mmol) and rinsed in with methanol (45 ml), while maintaining <5°. The mixture is vigorously stirred to dissolve the majority of the crude oil, then moderately stirred at 0-5° for 67 hrs. The mixture is cooled to -5° and hexanes (90 ml) are added. The phases are separated at <5° and the organic phase is washed at <5° with a mixture of methanol (50 ml) and water (7 ml). The pH of the combined aqueous phase is adjusted from 12.55 to 6.24 at <5° with acetic acid (1.52 g, 25.31 mmol, 4.21 equiv). The aqueous phase is concentrated, extracted with methylene chloride (2 x 40 ml), dried over magnesium sulfate, and concentrated to give a crude product. To a sample of the crude product (0.401 g) is added ether (1.0 ml). The resultant slurry is cooled to -30° and the precipitate collected by vacuum filtration, washed with cold ether and dried in a nitrogen stream to give the title compound, TLC R_f = 0.49 (ethyl acetate/hexanes, 1/1); HPLC r_t = 6.93 min; NMR (CDCl₃/CD₃OD, 1/1) 8.08, 7.80, 7.56, 7.22, 7.07-6.88, 3.98, 3.33-3.30, 2.50-2.37, 1.92-1.70, 1.58-1.50, 1.22-1.14, 0.76 and 0.72 δ ; CMR (CDCl₃/CD₃OD, 1/1) 169.05, 166.66, 148.66, 147.79, 141.99, 135.30, 129.21, 129.02, 128.70, 126.55, 123.51, 121.23, 105.13, 81.39, 42.58, 40.39, 40.09, 36.76, 30.38, 24.95, 17.44, 14.54 and 13.04 δ .

EXAMPLE 14 [3 α (R),6(R)]3-[1-(3-Aminophenyl)propyl]-5,6-dihydro-4-hydroxy-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (XVIII)

To a solution of [3 α (R),6(R)]5,6-dihydro-4-hydroxy-3-[1-(3-nitrophenyl)propyl]-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (XVII, EXAMPLE 13, 0.6993 g, 1.651 mmol) in THF (50 ml) is added palladium on carbon (5%, 50% water wet, 0.2574 g, 0.06048 mmol, 0.0366 equiv) and the mixture hydrogenated at 50 psi on a Parr shaker for 21 hrs. Celite (2.07 g) is added and the catalyst removed by vacuum filtration and rinsed with THF. The filtrate is concentrated to give the title compound, TLC R_f = 0.45 (ethyl acetate/hexanes, 1/1); HPLC r_t = 5.18 min.

EXAMPLE 15 [R-(R*,R*)]-N-[3-[1-[5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide (XIX)

To a mixture of [3 α (R),6(R)]3-[1-(3-aminophenyl)propyl]-5,6-dihydro-4-hydroxy-

6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (XVIII, EXAMPLE 14, crude 0.555 g, 1.378 mmol based on title compounds XIX), in methylene chloride (3.10 ml), DMSO (0.100 ml, 1.409 mmol, 1.02 equiv) and pyridine (0.56 ml, 6.92 mmol, 5.02 equiv) is added the crude mixture of 5-(trifluoromethyl)-2-pyridinesulfonyl chloride in methylene chloride prepared above (5.23 ml, ~2.3 mmol based on thiol, ~1.7 equiv) at -25 to -30° over 2 hours, titrating with the 5-(trifluoromethyl)-2-pyridinesulfonyl chloride mixture to an HPLC endpoint of 1.4 area% residual [3 α (R),6R]3-[1-(3-aminophenyl)propyl]-5,6-dihydro-4-hydroxy-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (XVIII, EXAMPLE 14). Aqueous hydrochloric acid (1 M, 6.2 ml, 6.2 mmol, 4.50 equiv) and ethyl acetate (5.2 ml) is added and the phases separated. The aqueous phase is washed with methylene chloride (10 ml) and the combined organic phases dried on magnesium sulfate and concentrated. This concentrate is loaded on a silica gel column (9.76 g silica gel) packed with ethyl acetate/hexanes (10/90) and the product eluted with the following ethyl acetate in hexanes mixtures (50 ml 10%, 100 ml 20%, 100 ml 30%, and 50 ml 40%). The eluent is combined and concentrated to an oil with an ethyl acetate chase. Ethyl acetate is added (5.2 ml) and the product precipitated by slow addition of heptane (15 ml). The resultant slurry is cooled to -30° and the precipitate collected by vacuum filtration, washed with a -30° mixture of ethyl acetate (1 ml) and heptane (4 ml) and dried in a nitrogen stream to give the title compound, mp = 86-89°; TLC R_f = 0.66 (ethyl acetate/hexane, 50/50); NMR (CD₃OD) 8.94, 8.19, 8.02, 7.25-6.97, 3.93, 2.68-2.52, 2.15-2.09, 1.96-1.64, 1.33, 0.88 and 0.83 δ ; CMR (CD₃OD) 169.9, 167.0, 161.6, 148.1, 147.6, 142.8, 137.7, 137.0, 130.1, 129.5, 129.3, 127.0, 126.1, 124.2, 122.6, 120.3, 106.2, 81.9, 43.6, 40.5, 40.5, 37.4, 30.9, 25.8, 17.9, 14.7 and 13.3 δ ; MS (CI, ammonia) m/z (relative intensity) 621 (1.7), 620 (5.4), 604 (1.1), 603 (3.4), 411 (12), 394 (12), 148 (100); IR (mull) 1596, 1413, 1359, 1326, 1177, 1149, 1074 and 720 cm⁻¹ (same solid state form as reference).

EXAMPLE 16 [3 α (R),6(R)]5,6-Dihydro-4-hydroxy-3-[(Z)-1-(3-nitrophenyl)propenyl]-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (XXV, major component) and [3 α (R),6R]5,6-dihydro-4-hydroxy-3-[(E)-1-(3-nitrophenyl)propenyl]-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (XXV, minor component)

(6R)-5,6-dihydro-4-hydroxy-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (VI, EXAMPLE 4, 50.0 g, 187 mmol) is combined with m-nitropropiophenone (33.5 g, 187.2 mmol) and 375 ml of THF. Pyridine is added (31.0 mL, 374 mmol), and the resultant mixture is stirred and cooled to below -5°. A solution is prepared by

adding titanium tetrachloride (31 ml, 280 mmol) to 80 ml of toluene, and this solution is added to the mixture in a controlled manner to maintain the reaction temperature below 10°. Toluene (15 ml) is used to rinse in all of the titanium tetrachloride solution and at the end of this addition, the reaction mixture is

5 warmed to between 35-45° and maintained in this range for about 16 hours. The reaction mixture is cooled to 0° and water (200 ml) is added in a single portion. This mixture is stirred until all solids dissolve. The mixture is warmed to at least 15° and then transferred to a separatory funnel using water (250 ml) and ethyl acetate (500 ml) to dilute the mixture. The aqueous layer is separated, removed,

10 extracted with ethyl acetate (150 ml) and discarded. The primary organic layer is washed sequentially with hydrochloric acid (1 N, 2 x 150 ml), water (150 ml) and saturated sodium bicarbonate (150 ml). Each wash is extracted with the ethyl acetate (150 ml) extract prior to disposal. At this point the primary organic layer and the extract are combined and concentrated under reduced pressure to give a

15 concentrate. The concentrate is then dissolved in methylene chloride (350 ml). This solution is extracted with a total of 500 ml of 1 N sodium hydroxide (4 x 50 ml, then 3 x 100 ml). The combined aqueous extracts are washed with a total of 500 ml of methylene chloride (4 x 50 ml, then 3 x 100 ml) and then treated with hydrochloric acid (3 N, 150 ml). The acidified mixture is extracted with methylene chloride (400

20 ml, then 6 x 100 ml) and the combined organic extracts are washed with water (200 ml) and then saline (200 ml). After drying further with anhydrous sodium sulfate, the mixture is filtered through a pad of magneson and then concentrated under reduced pressure to give the mixture of title compounds, TLC R_f = 0.18 for (Z)-isomer, 0.28 for (E)-isomer (ethyl acetate/hexane, 1/1); CMR (CDCl₃) 166.93, 166.53,

25 148.27, 142.53, 142.39, 140.96, 132.23, 132.12, 131.82, 131.74, 129.87, 129.12, 128.55, 128.14, 126.16, 121.67, 120.56, 101.09, 81.77, 39.78, 35.23, 29.73, 16.91, 15.75, 15.69 and 14.23 δ ; MS (CI + NH₃) m/z (relative intensity) 439 (100), 422 (18), 409 (9), 392 (9), 278 (9), 194 (10), 136 (9).

EXAMPLE 17 [3 α (R),6(R)]5,6-dihydro-4-hydroxy-3-[1-(3-nitrophenyl)propyl]-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (XVII)

30

[3 α (R),6(R)]5,6-Dihydro-4-hydroxy-3-[(Z)-1-(3-nitrophenyl)propenyl]-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (XXV, EXAMPLE 16, 4.24 g, 10 mmol) and [(1,5-cyclooctadiene)rhodium(I)-1,2-bis-(2R,5R)-dimethyl-phospholano]benzene[tetrafluoroborate (6.0 mg, 0.01 mmol) are combined in an inert

35 atmosphere and dissolved in 20 ml of deoxygenated methanol. The atmosphere is replaced with hydrogen at a pressure of 80 psig or more and the reaction is warmed

to 55° and stirred for 24 hours. At the end of this period, the reaction is cooled to 20-25° and the hydrogen is replaced with an inert atmosphere. The reaction mixture is concentrated under reduced pressure and the residue is crystallized from a methanol/water mixture (3/1) to give the title compound, TLC R_f = 0.49 (ethyl acetate/hexanes, 1/1); HPLC r_t = 6.93 min; NMR ($\text{CDCl}_3/\text{CD}_3\text{OD}$, 1/1) 8.08, 7.80, 7.56, 7.22, 7.07-6.88, 3.98, 3.33-3.30, 2.50-2.37, 1.92-1.70, 1.58-1.50, 1.22-1.14, 0.76 and 0.72 δ ; CMR ($\text{CDCl}_3/\text{CD}_3\text{OD}$, 1/1) 169.05, 166.66, 148.66, 147.79, 141.99, 135.30, 129.21, 129.02, 128.70, 126.55, 123.51, 121.23, 105.13, 81.39, 42.58, 40.39, 40.09, 36.76, 30.38, 24.95, 17.44, 14.54 and 13.04 δ .

10 EXAMPLE 18 (6R)-5,6-dihydro-4-hydroxy-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (CVI)

(R)-3-Hydroxy-3-(2-phenylethyl)hexanoic acid, (1R,2S)-norephedrine salt (CIV, 180 g; 486 mmol) is converted to (R)-3-hydroxy-3-(2-phenylethyl)hexanoic acid by slurrying the salt in methylene chloride (1100 ml) and adding hydrochloric acid (2M, 720 ml). The free acid is extracted into the methylene chloride and the mixture is azeotropically dried by atmospheric distillation with incremental addition of methylene chloride (700 ml total). The free acid mixture (350 ml) is added to a slurry of carbonyl-diimidazole (90.5 g, 558 mmol) in methylene chloride (80 ml) and pyridine (210 ml) at -10 to 0°. The mixture is warmed to 0° and stirred for an hour.

A slurry of malonate monoethyl ester magnesium salt is prepared by adding an acetone slurry of potassium malonate monoethyl ester (144 g, 846 mmol in 350 ml of acetone) to a slurry of magnesium chloride (72 g, 756 mmol) which has been prepared by the slow addition of acetone (250 ml) to a slurry of magnesium chloride in methylene chloride (100 ml). The malonate salt preparation is completed by atmospheric distillation to a volume of 350 ml.

The (R)-3-Hydroxy-3-(2-phenylethyl)hexanoyl imidazole mixture, from the carbonyl-diimidazole activation, is added to the magnesium ethyl malonate slurry at 10-20°. The mixture is warmed to 20-25° and stirred for approximately 16 hours. The reaction is quenched with the addition of hydrochloric acid (5N, 850 ml.) Methylene chloride (125 ml) is added and the phases separated. The product containing organic layer is washed with hydrochloric acid (1N, 400 ml) and then saturated sodium bicarbonate solution (500 ml). The organic phase is concentrated under vacuum to about 200 ml, methanol (700 ml) is added, and the vacuum concentration continued to a final volume of 150 ml. To the methanolic solution of the (R)-ethyl 5-hydroxy-3-oxo-5-(2-phenylethyl)-octanoate is added a methanolic

solution of potassium hydroxide (59.5 g of 85%; 902 mmoles dissolved in 200 ml of methanol) at 15-20°. The mixture is stirred for 16 hr at 20°. Water (350 ml) is added and the product containing aqueous layer is washed twice with methyl t-butyl ether (350 ml, each wash). The aqueous phase is acidified with hydrochloric acid (6 M, 220ml) and the product is extracted with toluene (550 ml). The toluene mixture is washed with water (150 ml) and concentrated under reduced pressure to 200 ml. The product is crystallized by the addition of branched octane (approx. 400 ml in two portions allowing crystallization to occur between additions). On cooling, the product is isolated by vacuum filtration, washed with branched octane, and dried at 20-25° to give the title compound.

EXAMPLE 19 5,6-dihydro-4-hydroxy-6-[1-(2-(4-substituted)phenyl)ethyl]-6-isopropyl-2H-pyran-2-ones (CVI)

Following the general procedure of EXAMPLES 1 thru 4 and making non-critical variations but starting with 4-hydroxy-, 4-amino-, 4-monoalkylamino or 4-dialkylamino- phenyl-2-methyl-3-pentanone (CI), the title compound is obtained.

EXAMPLE 20 (6S)-5,6-dihydro-4-hydroxy-6-[1-(2-phenyl)ethyl]-6-phenyl-2H-pyran-2-ones (CVI)

Following the general procedure of EXAMPLES 1 thru 4 and making non-critical variations but starting with 1,3-diphenyl-1-propanone (CI), the title compound is obtained.

EXAMPLE 21 *t*-Butyl-3-hydroxy-3-(2-phenylethyl)hexanoate (II)

Following the general procedure of EXAMPLE 1 and making non-critical variations, but using *t*-butyl acetate in place of ethyl acetate the title compounds is obtained. It is preferred that *t*-butyl acetate be used.





CHART A

CHART B


(VII)



(VIII)




(IX)


CHART C

(IX)


+



(IV)



(X)



(XI)




CHART C - continued

CHART D

5




10




15

20



25

30



(XVIII)




CHART D - continued


5

10


15

20


25




(XIX)

CHART E


(XX)




(XXI)




(XXII)




(XXIII)




(XXIV)




(XIII)

CHART F


(VI)



(XXV)



(XVII)

CHART G

CLAIMS

1. (R)-3-Hydroxy-3-(2-phenylethyl)hexanoic acid (IV) and pharmaceutically acceptable salts thereof.

5 2. A compound according to claim 1 where the pharmaceutically acceptable salts are selected from the group consisting of hydroxide, ammonia, tromethamine (THAM), 2-amino-2-(hydroxymethyl)-1,3-propanediol, (1R,2S)-norephedrine, (1S,2R)-norephedrine, (R)-2-amino-2-phenylethanol, (S)-2-amino-2-phenylethanol, (R)-1-phenylethylamine and (S)-1-phenylethylamine.

10

3. A compound according to claim 1 which is (R)-3-hydroxy-3-(2-phenylethyl)hexanoic acid, (1R,2S)-norephedrine salt.

4. (6R)-5,6-Dihydro-4-hydroxy-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one.

15

5. [3 α (R),6(R)]5,6-Dihydro-4-hydroxy-3-[1-(3-nitrophenyl)propyl]-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one (XVII).


6. (S)-methyl 3-(3-nitrophenyl)pentanoate.

20

7. [3 α (R),6(R)]5,6-Dihydro-4-hydroxy-3-[(Z)-1-(3-nitrophenyl)propenyl]-6-[1-(2-phenyl)ethyl]-6-propyl-2H-pyran-2-one.

8. A process for the production of the hydroxy lactone of formula (CVI)

25



(CVI)

30

where R₁ is:

C₁-C₆ alkyl,

cyclohexyl,

35

phenyl,

-CH₂-CH₂- ϕ R₁₋₁ where R₁₋₁ is

-OH (and protected forms thereof),
 -NH₂ (and protected forms thereof),
 -H,
 -NH-CO-CH₃,
 -N(-CO-CH₃)₂;

where R₂ is:


C₁-C₆ alkyl,
 cyclohexyl,
 phenyl,

-CH₂-CH₂-φR₂₋₁ where R₂₋₁ is

-OH (and protected forms thereof),
 -NH₂ (and protected forms thereof),
 -H,
 -NH-CO-CH₃,
 -N(-CO-CH₃)₂;

which comprises:

(1) contacting a salt of the formula (CIV)



with an acid to produce a free acid,

(2) extracting the free acid from the reaction mixture,

(3) contacting the free acid with an activating agent,

(4) contacting the reaction mixture of free acid/activating agent with malonate monoester and a divalent metal,

(5) contacting the reaction mixture of step (4) with an acid,

(6) contacting the reaction mixture of step (5) with a base in the presence of a C₁-C₄ alcohol, THF or DMF.

9. A process for the production of the hydroxy lactone of formula (CVI) according to claim 8 where the acid of step (1) is an inorganic acid or organic acid.

10. A process for the production of the hydroxy lactone of formula (CVI) according

to claim 9 where the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, citric acid, trifluoroacetic acid, chloroacetic acid, sodium hydrogen sulfate, potassium hydrogen sulfate.

5

11. A process for the production of the hydroxy lactone of formula (CVI) according to claim 10 where the acid is hydrochloric acid.

12. A process for the production of the hydroxy lactone of formula (CVI) according to claim 8 where the extraction of the free acid is performed with a nonpolar organic solvent.

13. A process for the production of the hydroxy lactone of formula (CVI) according to claim 12 where the nonpolar organic solvent is selected from the group consisting of methylene chloride, toluene, benzene, methyl acetate, ethyl acetate, methyl tert-butyl ether, ethyl ether and hexane.

14. A process for the production of the hydroxy lactone of formula (CVI) according to claim 13 where the solvent is methylene chloride.

20

15. A process for the production of the hydroxy lactone of formula (CVI) according to claim 8 where the activating agent is carbonyl-diimidazole.

16. A process for the production of the hydroxy lactone of formula (CVI) according to claim 8 where the process of step (3) is performed in the presence of a base.

17. A process for the production of the hydroxy lactone of formula (CVI) according to claim 16 where the base is selected from the group consisting of pyridine, 4-N,N-dimethylaminopyridine, dimethylaniline, diethylaniline, 2,6-lutidine, triethylamine, tributylamine and collidine.

30

18. A process for the production of the hydroxy lactone of formula (CVI) according to claim 17 where the base is pyridine.

19. A process for the production of the hydroxy lactone of formula (CVI) according to claim 8 where the malonate monoester is selected from the group consisting of

35

KO-CO-CH₂-CO-O-R_e where R_e is C₁-C₄ alkyl or phenyl.


20. A process for the production of the hydroxy lactone of formula (CVI) according to claim 19 where the malonate monoester is the C₁ or C₂ ester.
- 5 21. A process for the production of the hydroxy lactone of formula (CVI) according to claim 8 where the divalent metal is selected from the group consisting of Mg⁺², Ca⁺² and Zn⁺².
- 10 22. A process for the production of the hydroxy lactone of formula (CVI) according to claim 21 where the divalent metal is Mg⁺².
23. A process for the production of the hydroxy lactone of formula (CVI) according to claim 22 where the divalent metal is MgCl₂.
- 15 24. A process for the production of the hydroxy lactone of formula (CVI) according to claim 8 where the acid of step (5) is selected from the group consisting of is an inorganic acid or organic acid.
- 20 25. A process for the production of the hydroxy lactone of formula (CVI) according to claim 24 where the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, citric acid, trifluoroacetic acid, chloroacetic acid, sodium hydrogen sulfate, potassium hydrogen sulfate.
- 25 26. A process for the production of the hydroxy lactone of formula (CVI) according to claim 25 where the acid is hydrochloric acid.
27. A process for the production of the hydroxy lactone of formula (CVI) according to claim 8 where the base in step (6) is selected from the group consisting of organic bases and inorganic bases.
- 30 28. A process for the production of the hydroxy lactone of formula (CVI) according to claim 27 where the base is selected from the group consisting of hydroxide, C₁-C₄ alkoxide and carbonate.
- 35

29. A process for the production of the hydroxy lactone of formula (CVI) according to claim 28 where the base is hydroxide.

30. A process for the production of the hydroxy lactone of formula (CVI) according to claim 8 where the excess malonate monoester is removed by extraction prior to step (6).

31. A process for the production of the hydroxy lactone of formula (CVI) according to claim 30 where the malonate monoester is removed by extraction with a base selected from the group consisting of hydroxide, tertiary amine bases, carbonate and bicarbonate.

32. A process for the production of the hydroxy lactone of formula (CVI)



where R_1 is:

C_1 - C_6 alkyl,
cyclohexyl,
phenyl,

$-\text{CH}_2-\text{CH}_2-\phi R_{1-1}$ where R_{1-1} is

$-\text{OH}$ (and protected forms thereof),
 $-\text{NH}_2$ (and protected forms thereof),
 $-\text{H}$,
 $-\text{NH}-\text{CO}-\text{CH}_3$,
 $-\text{N}(-\text{CO}-\text{CH}_3)_2$;

where R_2 is:

C_1 - C_6 alkyl,
cyclohexyl,
phenyl,

$-\text{CH}_2-\text{CH}_2-\phi R_{2-1}$ where R_{2-1} is

$-\text{OH}$ (and protected forms thereof),

-NH₂ (and protected forms thereof),
 -H,
 -NH-CO-CH₃,
 -N(-CO-CH₃)₂;

5 which comprises:

(1) contacting the anion of the formula (CIV)



or the free acid form thereof with an activating agent,

(2) contacting the reaction mixture of free acid/activating agent with
 15 malonate monoester and a divalent metal,
 (3) contacting the reaction mixture of step (4) with an acid,
 (4) contacting the reaction mixture of step (5) with a base in the presence of a
 C₁-C₄ alcohol, THF or DMF.

20 33. A process for the production of the hydroxy lactone of formula (CVI) according
 to claim 32 where the activating agent is carbonyl-diimidazole.

34. A process for the production of the hydroxy lactone of formula (CVI) according
 to claim 32 where the process of step (1) is performed in the presence of a base.

25 35. A process for the production of the hydroxy lactone of formula (CVI) according
 to claim 34 where the base is selected from the group consisting of pyridine, 4-N,N-
 dimethylaminopyridine, dimethylaniline, diethylaniline, 2,6-lutidine, triethylamine,
 tributylamine and collidine.

30 36. A process for the production of the hydroxy lactone of formula (CVI) according
 to claim 35 where the base is pyridine.

35 37. A process for the production of the hydroxy lactone of formula (CVI) according
 to claim 32 where the malonate monoester is selected from the group consisting of
 KO-CO-CH₂-CO-O-R_e where R_e is C₁-C₄ alkyl or phenyl.

38. A process for the production of the hydroxy lactone of formula (CVI) according to claim 37 where the malonate monoester is the C₁ or C₂ ester.
- 5 39. A process for the production of the hydroxy lactone of formula (CVI) according to claim 32 where the divalent metal is selected from the group consisting of Mg⁺², Ca⁺² and Zn⁺².
- 10 40. A process for the production of the hydroxy lactone of formula (CVI) according to claim 39 where the divalent metal is Mg⁺².
41. A process for the production of the hydroxy lactone of formula (CVI) according to claim 40 where the divalent metal is MgCl₂.
- 15 42. A process for the production of the hydroxy lactone of formula (CVI) according to claim 32 where the acid of step (3) is selected from the group consisting of is an inorganic acid or organic acid.
- 20 43. A process for the production of the hydroxy lactone of formula (CVI) according to claim 42 where the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, citric acid, trifluoroacetic acid, chloroacetic acid, sodium hydrogen sulfate, potassium hydrogen sulfate.
- 25 44. A process for the production of the hydroxy lactone of formula (CVI) according to claim 43 where the acid is hydrochloric acid.
- 30 45. A process for the production of the hydroxy lactone of formula (CVI) according to claim 32 where the base in step (4) is selected from the group consisting of organic bases and inorganic bases.
- 35 46. A process for the production of the hydroxy lactone of formula (CVI) according to claim 45 where the base is selected from the group consisting of hydroxide, C₁-C₄ alkoxide and carbonate.
47. A process for the production of the hydroxy lactone of formula (CVI) according

to claim 46 where the base is hydroxide.

48. A process for the production of the hydroxy lactone of formula (CVI) according to claim 32 where the excess malonate monoester is removed by extraction prior to
5 step (4).

49. A process for the production of the hydroxy lactone of formula (CVI) according to claim 48 where the malonate monoester is removed by extraction with a base selected from the group consisting of hydroxide, tertiary amine bases, carbonate and
10 bicarbonate.

INTERNATIONAL SEARCH REPORT

In tional Application No

PCT/US 98/17993

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D309/32 C07C59/48 C07C205/56

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 30670 A (THE UPJOHN CO.) 16 November 1995 cited in the application see claims 27,29,33,35,37 ---	1-49
A	WO 94 11361 A (THE UPJOHN CO.) 26 May 1994 cited in the application see charts A,B,I,J ---	1-49
A	FR 2 096 877 A (HEXACHIMIE) 3 March 1972 see claim 1 ---	1-49
A	WO 95 14012 A (PARKE DAVIS & CO) 26 May 1995 see page 31 - page 39 --- -/--	1-49

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

18 December 1998

Date of mailing of the international search report

12/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

In ternational Application No

PCT/US 98/17993

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>S. THAISRIVONGS ET AL.: JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 23, 1996, pages 4630-4642, XP002088571 WASHINGTON US cited in the application see page 4631</p> <p style="text-align: center;">-----</p>	1-49

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/17993

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9530670 A	16-11-1995	AU 2462695 A BR 9507615 A CA 2187523 A CN 1150424 A CZ 9603172 A EP 0758327 A FI 964441 A HU 77601 A JP 9512821 T NO 964676 A NZ 285510 A PL 317061 A SK 138496 A	29-11-1995 09-09-1997 16-11-1995 21-05-1997 16-04-1997 19-02-1997 05-11-1996 29-06-1998 22-12-1997 06-01-1997 25-03-1998 03-03-1997 04-06-1997
WO 9411361 A	26-05-1994	AU 687368 B AU 5549394 A CA 2145661 A CN 1090279 A CZ 9501078 A EP 0668860 A FI 952302 A JP 8503216 T NO 951899 A NZ 258013 A PL 308998 A SK 61695 A ZA 9308019 A	26-02-1998 08-06-1994 26-05-1994 03-08-1994 13-12-1995 30-08-1995 11-05-1995 09-04-1996 12-07-1995 24-02-1997 18-09-1995 11-10-1995 28-04-1995
FR 2096877 A	03-03-1972	BE 769597 A CH 528502 A CH 530393 A DE 2134094 A GB 1355667 A GB 1355668 A NL 7109472 A	16-11-1971 30-09-1972 15-11-1972 20-01-1972 05-06-1974 05-06-1974 11-01-1972
WO 9514012 A	26-05-1995	US 5840751 A AU 695088 B AU 4097497 A AU 680064 B AU 8090094 A AU 689158 B AU 8125694 A BG 100563 A CA 2176041 A CA 2176043 A CZ 9601368 A EP 0729463 A EP 0729464 A FI 962021 A FI 962022 A HR 940935 A HR 940936 A HU 77668 A HU 75225 A JP 9505292 T JP 9505294 T NO 962017 A	24-11-1998 06-08-1998 08-01-1998 17-07-1997 06-06-1995 26-03-1998 06-06-1995 31-12-1996 26-05-1995 26-05-1995 17-12-1997 04-09-1996 04-09-1996 12-07-1996 12-07-1996 30-04-1997 31-08-1997 28-07-1998 28-04-1997 27-05-1997 27-05-1997 08-07-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/17993

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9514012 A		NO 962018 A	04-07-1996
		PL 314483 A	16-09-1996
		SK 64696 A	05-03-1997
		WO 9514011 A	26-05-1998
		US 5789440 A	04-08-1998
		ZA 9409148 A	21-07-1995
		ZA 9409151 A	29-07-1995
